President & Chief Executive Officer (CEO)
Jonas has worked over 25 years in the Life Science sector. He is an assistant professor in pharmacology at Uppsala University, he has a B.Sci. in Chemistry from University of Stockholm, and a Ph.D. in Experimental Neurology from Uppsala University, post-doctoral studies at University of Southern California, School of Pharmacy in LA. He has also received education in strategic planning and business management. Jonas has previously held executive roles in biotech companies in Sweden, US and Switzerland. Most recently, he served as CEO for the Swiss biotech BOWS Pharmaceuticals SA, and prior held senior and executive positions in Pharmacia, Biovitrum, Sequenom and Invitrogen. Jonas has worked as CEO in the group since 2010. Between 2015 and 2017 he was consultant CEO. He was employed as president and CEO for the group from May 1, 2017.
Other Assignments: Chairman of Axelar AB and EffRx Pharmaceuticals SA as well as principal of his own consultancy practice Edge of the World Strategies Corporation.
Share Holding in Promore Pharma: 15,000 shares.
Chief Financial Officer (CFO)
Jenni has extensive professional experience from the financial markets, having worked with corporate finance for over ten years with Handelsbanken Markets and Alfred Berg Fondkommission/ABM AMRO. Jenni has also worked three years as a stock analytics at Standard & Poor’s and at ABG Sundal Collier. She has been business area manager at Global Health Partners AB. Jenni has a training in economy from Stockholm School of Economics, and has served as CFO of Promore Pharma since 2016.
Other Assignments: Jenni is a board director in Hemcheck Sweden AB as well as principal of her own consultancy practice The C Story AB.
Share Holding in Promore Pharma: 7,000 shares.
Chief Scientific Officer (CSO)
Margit has over 15 years of experience in pharmaceutical research and development. She has had assignments at companies such as AstraZeneca, Arexis, and Swedish Orphan Biovitrum. Margit holds an associate professorship in Molecular Medicine at Sahlgrenska Academy, Sweden. She has a Ph.D. in Molecular and Cellular Biology from the University of Gothenburg. Margit joined the company in 2007 and has since then been responsible for regulatory affairs strategy and clinical development.
Other Assignments: Margit is a director of the board in Sixera AB, she is CEO of to IP holding companies ScandiCure AB and Alexera AB and she is CEO and chairman of her own consultancy practice Arexela AB, an intellectual property holding company.
Share Holding in Promore Pharma: No current holding.
Holdings as of December 31, 2019.